Price$264.99+1.44 (+0.55%)
01:45 PM07:45 PM
News · 26 weeks131+70%
2026-03-012026-08-23
Mix5890d
- Other38(66%)
- SEC Filings11(19%)
- Earnings3(5%)
- Insider3(5%)
- Analyst2(3%)
- Dividends1(2%)
Latest news
25 items- PRAbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer PipelineClinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentationAdditionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer (SCLC) to be sharedResearch reflects AbbVie's strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted antibody-drug conjugates (ADCs) and the potential for novel combination approachesNORTH CHICAGO, Ill., Aug. 21, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cance
- INSIDEREVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- SECAbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRA New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.Issued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time and gravity take away: fill a wrinkle, restore lost volume, reshape a contour. Now a shift in the underlying science is pointing toward something more ambitious. Instead of simply replacing volume, a growing body of research is asking whether the body's own tissue can be prompted to rebuild itself, and a new commercial category is beginning to form around that idea. At the center of the science is a structure most people have never heard of, the extracellular matrix, the frame
- PRAbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of SupportSince its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarship Now a renewable award, students may earn the AbbVie Immunology Scholarship for up to four yearsRecipients live with conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritisNORTH CHICAGO, Ill., Aug. 18, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology Scholarship, as the program marks its 10th year. During the past decade, AbbVie has invested more than $6 million through the
- ANALYSTAbbVie upgraded by Wolfe Research with a new price targetWolfe Research upgraded AbbVie from Peer Perform to Outperform and set a new price target of $300.00
- PRThe GLP-1 Boom Created a Tissue Gap Fillers Were Not Built ForRENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs themselves were never designed to address. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to address. On August 3, 2026, Conexeu Sciences Inc. (NASDAQ:CNXU) President and Chief Executive Officer Miles Harrison sat down with IPO Edge for a fireside chat that put that
- PRAllergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics PracticesUpdated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growthIntroduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customersIRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges® (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the program now introduces simpler savings, greater benefits transparency and expanded opportunities for practic
- SECSEC Form 424B5 filed by AbbVie Inc.424B5 - AbbVie Inc. (0001551152) (Filer)
- SECAbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- ANALYSTAbbVie upgraded by Erste GroupErste Group upgraded AbbVie from Hold to Buy
- SECSEC Form FWP filed by AbbVie Inc.FWP - AbbVie Inc. (0001551152) (Subject)
- PREvery Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next OneNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) to InMode (NASDAQ:INMD) and Anika Therapeutics (NASDAQ:ANIK), built enormous businesses around them. Now a wave of new demand is exposing the limits of the existing categories, and a preclinical company, Con
- SECSEC Form 424B5 filed by AbbVie Inc.424B5 - AbbVie Inc. (0001551152) (Filer)
- PRAllergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle ProminenceIf approved, BOTOX® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle prominence and patient satisfaction with treatment IRVINE, Calif., Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearan
- PRUBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine TreatmentUBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies.CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults.Migraine affects an estimated 5 million Canadians with the highest prevalence in women1 and individuals in their 30s and 40s.2MONTREAL, Aug. 4, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with
- SECSEC Form 10-Q filed by AbbVie Inc.10-Q - AbbVie Inc. (0001551152) (Filer)
- SECAbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Reports Second-Quarter 2026 Financial ResultsReports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0.17 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $16.990 Billion, an Increase of 10.2 Percent on a Reported Basis or 9.5 Percent on an Operational BasisSecond-Quarter Global Net Revenues from the Immunology Portfolio Were $8.786 Billion, an Increase of 15.1 Percent on a Reported Basis, or 14.6 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $5.505 Billion; Global Rinvoq Net Revenues Were $2.525 Billion; Global Humira Net Rev
- PRJUVÉDERM® Day Returns to U.S. on August 19Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē MembersThis summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approvalJoin Allē today to take advantage of limited time offers, while supplies lastNORTH CHICAGO, Ill., July 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 19, 2026, with exclusive JUVÉDERM® offers for Allē Members. Allergan Aesthetics invites aesthetic providers and consumers to join in celebrating JUVÉDERM®'s continued aesthetics leadership as the numb
- PRAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental VitiligoRINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV)The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total body (T-VASI 50) and facial repigmentation (F-VASI 75) from baseline at week 48, versus placebo1NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemi
- PRAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia AreataRINVOQ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA)Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score ≤ 20) and improvements in eyebrows and eyelashes at week 241RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and
- PRAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsBoey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeksBoey® offers a differentiated treatment option for many people who are curious about facial injectables²NORTH CHICAGO, Ill., July 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows
- PRSkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and DevelopmentSkinMedica® launches Regenerative Science Advisory Board to shape future innovationExpands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovationDebuts flagship retail experiences designed to support practice and patients' needs IRVINE, Calif., July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE:ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience. "Stemming from its origins in wound-healing research, SkinMedica was founded on the principles of regenerative skincare," said
- PROne Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsIssued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P
ABBV FAQ
8 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.Does ABBV pay a dividend?
ABBV's most recent ex-dividend date was 2026-07-15 with a cash dividend of $1.73 per share. No future ex-date is on file yet.What are analysts saying about ABBV?
AbbVie Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-08-13.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.